Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.74 and traded as low as $0.58. Vaxart shares last traded at $0.60, with a volume of 970,174 shares trading hands.
Analysts Set New Price Targets
Separately, Oppenheimer started coverage on shares of Vaxart in a report on Thursday, August 15th. They issued an "outperform" rating and a $4.00 target price for the company.
View Our Latest Analysis on VXRT
Vaxart Price Performance
The firm's 50-day moving average price is $0.70 and its 200-day moving average price is $0.74. The company has a market cap of $134.67 million, a price-to-earnings ratio of -1.44 and a beta of 0.62.
Hedge Funds Weigh In On Vaxart
A number of large investors have recently bought and sold shares of VXRT. Mesirow Financial Investment Management Inc. boosted its holdings in shares of Vaxart by 100.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 20,000 shares during the period. Sequoia Financial Advisors LLC bought a new position in Vaxart in the 2nd quarter worth about $65,000. XTX Topco Ltd increased its stake in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 122,387 shares during the period. Monaco Asset Management SAM bought a new stake in shares of Vaxart during the second quarter valued at approximately $402,000. Finally, Geode Capital Management LLC boosted its position in shares of Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock worth $2,160,000 after buying an additional 346,725 shares during the period. Institutional investors own 18.05% of the company's stock.
Vaxart Company Profile
(
Get Free Report)
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Read More
Before you consider Vaxart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.
While Vaxart currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
